Influence of Gastrointestinal Symptoms on Patient Global Assessment in Patients with Rheumatoid Arthritis
- PDF / 769,187 Bytes
- 8 Pages / 595.276 x 790.866 pts Page_size
- 0 Downloads / 221 Views
MEDICINE
Influence of Gastrointestinal Symptoms on Patient Global Assessment in Patients with Rheumatoid Arthritis Shuji Asai 1 & Nobunori Takahashi 1 & Kaoru Nagai 2 & Tatsuo Watanabe 1,3 & Takuya Matsumoto 1,4 & Nobuyuki Asai 1,5 & Yasumori Sobue 1 & Naoki Ishiguro 1 & Toshihisa Kojima 1 Accepted: 16 April 2020 / Published online: 5 May 2020 # Springer Nature Switzerland AG 2020
Abstract This study aimed to determine the influence of gastrointestinal (GI) symptoms on patient global assessment (PGA) in patients with rheumatoid arthritis (RA). This cross-sectional study examined 837 patients with RA treated in our department between April 1 and September 30, 2017. GI symptoms were evaluated by the Gastrointestinal Symptom Rating Scale, wherein a score of ≥ 2 was considered “symptomatic.” PGA and proportion of PGA ≤ 1 were compared between symptomatic and asymptomatic patients. Factors associated with achievement of PGA ≤ 1 were assessed with logistic regression models. Of our study population, 28%, 24%, 28%, 28%, and 45% had reflux, abdominal pain, indigestion, diarrhea, and constipation, respectively, and 64% had at least one GI symptom. The symptomatic group had a significantly higher PGA score than the asymptomatic group in all GI symptoms (P < 0.001 for all comparisons). The proportion of patients with a PGA ≤ 1 in the symptomatic group was significantly lower than that in the asymptomatic group for reflux (20% vs. 37%), abdominal pain (21% vs. 36%), indigestion (18% vs. 38%), diarrhea (18% vs. 38%), and constipation (24% vs. 39%) (P < 0.001 for all comparisons). All GI symptoms were significantly associated with achievement of PGA ≤ 1 in patients without significant joint inflammation; this association was not observed for reflux and abdominal pain in patients with significant joint inflammation. GI symptoms can be one of the drivers of PGA in patients with RA, particularly in those without significant joint inflammation. Keywords Rheumatoid arthritis . Gastrointestinal symptoms . Patient-reported outcomes . Visual analog scale . Drug therapy
Introduction The ultimate goals of rheumatoid arthritis (RA) treatment are to prevent structural damage and normalize function by sustaining clinical remission [1]. Although newer medications This article is part of the Topical Collection on Medicine * Shuji Asai [email protected] 1
Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi 466-8560, Japan
2
Department of Nursing, Nagoya University Hospital, Nagoya, Japan
3
Department of Orthopedic Surgery, Daido Hospital, Nagoya, Japan
4
Department of Rheumatology, Shizuoka Kosei Hospital, Shizuoka, Japan
5
Department of Orthopedic Surgery and Rheumatology, Nagoya Medical Center, Nagoya, Japan
including biologics and more selective treatment strategies have enabled more patients with RA to achieve clinical remission, even patients who achieved clinical remission based on previous criteria (e.g., Disease Activity Score in 28 joints (DAS28)) ca
Data Loading...
